Strategies to reduce the immunogenicity that occurs following treatment with most biologic agents are a growing subject of investigation. A novel approach to induce tolerance to a therapeutic monoclonal antibody, alemtuzumab, has yielded promising results.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Wolbink, G. J., Aarden, L. A. & Dijkmans, B. A. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr. Opin. Rheumatol. 21, 211–215 (2009).
Baert, F. et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 348, 601–608 (2003).
Bartelds, G. M. et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann. Rheum. Dis. 66, 921–926 (2007).
Somerfield, J. et al. A novel strategy to reduce the immunogenicity of biological therapies. J. Immunol. 185, 763–768 (2010).
Weinblatt, M. E. et al. CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study. Arthritis Rheum. 38, 1589–1594 (1995).
Coles, A. J. et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N. Engl. J. Med. 359, 1786–1801 (2008).
Gilliland, L. K. et al. Elimination of the immunogenicity of therapeutic antibodies. J. Immunol. 162, 3663–3671 (1999).
Maini, R. N. et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41, 1552–1563 (1998).
Colombel, J. F. et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N. Engl. J. Med. 362, 1383–1395 (2010).
Parker, A. S., Zheng, W., Griswold, K. E. & Bailey-Kellogg, C. Optimization algorithms for functional deimmunization of therapeutic proteins. BMC Bioinformatics 11, 180 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Krieckaert, C., Bartelds, G. & Wolbink, GJ. Immunogenicity of biologic therapies—we need tolerance. Nat Rev Rheumatol 6, 558–559 (2010). https://doi.org/10.1038/nrrheum.2010.153
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2010.153
This article is cited by
-
Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles
Nature Nanotechnology (2016)
-
Paradoxical Expansion of Th1 and Th17 Lymphocytes in Rheumatoid Arthritis Following Infliximab Treatment: a Possible Explanation for a Lack of Clinical Response
Journal of Clinical Immunology (2015)
